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A b s t r a c t
Although tumour recurrence is an important and not infrequent event in meningiomas, predictive immunohistochemical 
markers have not been identified yet. The aim of this study was to address this clinically relevant problem by systematic 
retrospective analysis of surgically completely resected meningiomas with and without recurrence, including tumour 
samples from patients who underwent repeat surgeries. Three established immunohistochemical markers of routine 
pathological meningioma work-up have been assessed: the proliferative marker Ki-67 (clone Mib1), the tumour sup-
pressor gene p53 and progesterone receptor (PR). All these proteins correlate with the tumour WHO grade, however the 
predictive value regarding recurrence and progression in tumour grade is unknown.
One hundred and fourteen surgical specimens of 70 meningioma patients (16 male and 54 female) in a 16 years’ inter-
val have been studied. All tumours had apparently complete surgical removal. On Mib1, PR and p53 immunostained 
sections, the percentage of labelled tumour cells, the staining intensity and the multiplied values of these parameters 
(the histoscore) was calculated. Results were statistically correlated with tumour WHO grade, (sub)type, recurrence and 
progression in WHO grade at subsequent biopsies. 
Our results confirmed previous findings that the WHO grade is directly proportional to Mib1 and p53 and is inversely 
proportional to the PR immunostain. We have demonstrated that Mib1 and p53 have a significant correlation with and 
predictive value of relapse/recurrence irrespective of the histological subtype of the same WHO grade. As a quantitative 
marker, Mib1 has the best correlation with a percentage of labelled cells, whereas p53 with intensity and histoscore.
In conclusion, the immunohistochemical panel of PR, p53, Mib1 in parallel with applying standard diagnostic criteria 
based on H&E stained sections is sufficient and reliable to predict meningioma recurrence in surgically completely resect-
ed tumours.
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Introduction
Meningioma is one of the most frequent brain 
tumours [9]. According to the World Health Orga-
nization (WHO) classification, there are several 
subtypes like meningothelial, fibrous, transitional, 
psammomatous, angiomatous, microcystic, secre-
tory, lymphoplasmacyte-rich, metaplastic, choroid, 
clear cell, rhabdoid, papillary and other rare mor-
phological phenotypes [6,21]. The assigned WHO 
grade I-III reflects the probable prognosis which is 
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determined by the subtype and/or specified mor-
phological features such as mitotic rate, presence or 
absence of small geographic necrosis, nucleus-cyto-
plasm ratio an others [21]. Although tumour recur-
rence is an important and not infrequent event, our 
knowledge on predisposing factors is rather limit-
ed. The risk of recurrence increases with the WHO 
grade being 7-25% in WHO grade I, 30-50% in WHO 
grade II and 50-95% in WHO grade III [27,28,32,33]. 
The extent of resection assessed by the Simpson 
Grading System influences recurrence rates which 
is one reason of the wide range of probability [30]. 
The Simpson Grading System classifies the com-
pleteness of removal in a 5-tier scale ranging from 
macroscopically complete removal (grade I) to sim-
ple decompression with or without biopsy (grade V). 
Skull irradiation, inherited mutation of the NF2 gene 
(neurofibromatosis type 2) and epigenetic factors 
may also predispose to recurrence [22,23].
Another important phenomenon is tumour pro-
gression to a higher WHO grade. However, the risk 
and probability of progression remains rather unpre-
dictable – even less so than tumour recurrence. 
Hence, there is a  growing clinical need to identify 
additional and better predictors for recurrence and 
tumour progression than the currently used his-
tological grade and extent of resection. Because 
immunohistochemistry has been routinely used in 
the pathological diagnostic practice for decades, the 
search for predictive immunohistochemical markers 
is of importance. In our study we focussed on 3 well-
known immunohistochemical markers in routine 
pathological work-up of meningioma: the prolifera-
tive marker Ki-67 (clone Mib1), the tumour suppres-
sor gene p53 and progesterone receptor. All these 
proteins have been studied in meningioma and the 
correlation with tumour grade has been confirmed 
by several studies. However, the predictive value 
regarding recurrence and progression in tumour 
grade remains unknown. The aim of this study is 
to address these clinically relevant questions by 
a systematic retrospective analysis of meningiomas 
with and without recurrence, with special emphasis 
on tumour samples from patients who underwent 
repeat surgeries due to tumour recurrence.
p53 is one of the major tumour suppressor pro-
teins. The physiological functions of p53 are cell 
cycle regulation and conservation of the stability 
of the genome by preventing mutations, therefore 
it is called ‘the guardian of the genome’ [17]. More 
than 50 percent of human tumours carries a dele-
tion or mutation of the p53 genes (TP53) [13]. p53 
can be activated by DNA damage, oxidative stress, 
osmotic shock, ribonucleotide depletion or oncogene 
expression. The activation is marked by an increase 
in the half-life of p53 and a change of its conforma-
tion [16], therefore shows increased Labelling Index 
(LI) with immunohistochemistry with the polyclon-
al anti bodies routinely used in tumour diagnostics. 
The anticancer activity of p53 is through sever-
al mechanisms: it activates DNA repair proteins, 
induces growth arrest at the G1/S regulation point 
through p21 or initiates apoptosis if the DNA dam-
age is irreversible [12]. It has been investigated also in 
meningioma and several studies showed a positive 
correlation with the grade and tumour recurrence 
[4,7,8,14,15,24,26], whereas authors reported the 
grade as an independent predictive factor of recur-
rences with high Mib1 and p53 LI being a supportive 
marker helpful in borderline cases [31].
Ki-67 is necessary for cellular proliferation; it is 
present during all active phases of the cell cycle, 
and absent from the G0 phase. Mib1 is the usually 
applied clone of the Ki-67 antibody which is widely 
used as a proliferative marker in the routine diagnos-
tic work-up. The Mib1 LI shows a strong correlation 
with tumour growths, relapse/recurrence, length 
of disease free survival in various tumours [2,3,34] 
including meningioma [18,19].
Progesterone receptor (PR) is a steroid hormone 
receptor. It has been demonstrated that menin-
gioma cells show positivity for PR; the ratio of the 
positive cells is inversely proportional to the WHO 
grade [18,27]. Also described earlier that the cellular 
biosynthesis of PR in meningioma is not oestrogen 
regulated as it is other sex steroid in tissues [5,7]. 
PR is encoded by the PGR gene on the long arm of 
chromosome 11. In a  physiological situation after 
binding the progesterone hormone, the receptor 
undergoes a  dimerization and is transported to 
the nucleus to bind to the DNA and induce tran-
scription. Both forms (progesterone receptor A and 
progesterone receptor B) have a regulatory domain, 
a DNA binding domain, a hinge section and a ligand 
binding domain, but only the PR-B form possesses 
a transcription activation function.
The Mib1 antibody, p53 and PR are widely used 
immunohistochemical markers in meningioma diag-
nosis. In high-grade meningioma, the Mib1 LI is high-
er [1,4,28,29]. In our previous study we have reported 
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a significant correlation between the frequency and 
intensity of p53 immunostaining and WHO grade 
[10]. The reduced of PR immunoreactivity is anoth-
er known feature in the high grades of meningioma 
[18,20,25].
The aim of this study is to establish an easy-to-
use immunohistochemical panel for the routine neu-
ropathological use, which can predict meningioma 
relapse/recurrence. For validation we analysed the 
changes in immunohistochemical characteristics and 
expression patterns during relapse/recurrence and 
examined their relation to tumour grade.
Material and methods
One hundred and fourteen surgical specimens of 
70 meningioma patients (16 male and 54 female) in 
a 16 years’ interval have been retrospectively stud-
ied. All cases were revised by a  consultant neuro-
pathologist (TH) and divided into three grades and 
histological subtypes according to the WHO classifi-
cation [21].
We established two study groups: patients with 
one or more recurrence/relapse(s) (R/R group) and 
patients with meningioma without any radiologi-
cal or post mortem evidence of recurrence/relapse 
(non-R/R group). Only cases with apparently com-
plete surgical removal and no evidence of residual 
tumour on post-operative MRI were included.
After the surgical removal tissue samples were 
processed to generate sections from formalin fixed 
and paraffin embedded (FFPE) blocks which were 
stained with haematoxylin-eosin (H&E). One repre-
sentative tissue block was selected per case. From 
these blocks tissue micro arrays (TMAs) were built. 
Each TMA contained samples from 10 cases (three 
samples from each cases) plus 2 normal brain tissue 
samples in the left upper corner as a  reference to 
enable specimen identification in the TMA (Fig. 1). In 
total 12 TMA were built, containing tissue samples 
from 114 neurosurgical interventions.
Immunohistochemistry (IHC) was performed ac-
cording to standardized methods. In brief, 4 µm thick 
sections from TMA blocks were stained with p53 
mouse monoclonal antibody (clone DO-7, M7001, 
DAKO, Glostrup, Denmark); PR antibody (NCL-PGR-312, 
clone 16, Novocastra, Newcastle, UK) and anti-Ki-67 
antibody (clone Mib1, M7240, DAKO, Glostrup, Den-
Fig. 1. Low magnification image of histological slide stained with haematoxylin-eosin, made from tissue 
microarray (TMA) paraffin block. In the upper left corner there are two tissue (brain) samples for guidance 
regarding localization. The numbers from 1 to 10 represent the individual cases. Every ‘donor’ case have 3 dif-
ferent samples in the ‘recipient’ block. Scale bar 5 mm.
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mark) according to the manufacturer’s protocol with 
1 : 100, 1 : 100 and 1 : 200 dilution for p53, PR and 
Ki-67, respectively. Sections were incubated with the 
primary antibody for 6 hours at room temperature; 
the visualization was performed with SuperSensi-
tive™ One-step Polymer-HRP Detection System on 
Leica Bond Max™ fully automated IHC stainer with 
negative controls (omitting the primary antibody).
All of the H&E and immunostained TMA sections 
were scanned with a Panoramic Scanner (3DHistech, 
Budapest, Hungary). Two digital images were taken 
at 400x magnification from each tissue samples, in 
total 6 from each case. According to the intensity 
of nuclear staining of cells, 4 semi quantitative scores 
were applied: 0 (none), 1+ (weak), 2+ (moderate) and 
3+ (strong) (Fig. 2).
Images in 10 reference cases were analysed quan-
titatively with ImageJ (NIH, Bethesda, USA) soft-
ware Cell Counter function, to determine the exact 
percentage of immunopositive cells (Fig. 3). These 
images were used as reference cases to aid accu-
rate semi-quantitative assessment in all cases. This 
is a method easily and reliably applicable in the rou-
tine pathological diagnostic practice, similarly to the 
assessment of percentage of immunopositive cells in 
other tumours.
Not only the percentage value of immunopositive 
cells but also the average labelling intensity score 
(0-3+; for reference images see Fig. 2) of the stain-
ing were calculated in each picture. Similarly to the 
histoscore of breast carcinoma i.e. the multiple of 
the percentage of the positive cells and the average 
intensity of the positive cell nuclei [11] were calcu-
lated.
Data were analysed with SPSS 22.0 for Win-
dows (IBM, Armonk, NY, USA) statistical programme, 
using Kruskal-Wallis H-test, Mann-Whitney U-test 
and Wilcoxon signed ranks test. The patients were 
grouped by the grades (65 WHO grade I; 33 WHO 
grade II and 16 WHO grade III) and also based on the 
recurrence or relapse (R/R group) showed up at least 
5 years after resection: patients without recurrence 
or relapse (non-R/R group), patients with definitive 
relapse or recurrence (R/R group).
The non-R/R cases were WHO grade I, while the 
R/R group have 18 WHO grade I, 9 WHO grade II and 
2 WHO grade III tumour in the 1st histological sample. 
Ethical approval has been obtained from the Insti-
tutional Research Ethics Committee (Number: DEOEC 
RKEB: 2437-2005).
Results
The 70 patients’ average age was 56 years at the 
time of the first pathological examination. There 
were no significant differences between the R/R 
group and the non-R/R group. There were 16 patients 
(3 male and 13 female; average age 54 years) without 
recurrence or relapse (non-R/R group) with at least 
5 years’ survival after surgery and 31 patients (8 male 
and 23 female; average age 53 years, overall time of 
recurrence 19.6 months) with definitive relapse or 
recurrence (R/R group). Further 23 patients (5 male 
and 18 female, average age 59 years) were operated 
within 5 years without recurrence/relapse; however 
the time window was too short to include them in 
the non-R/R group. There were 65 WHO grade I cases, 
33 WHO grade II cases and 16 WHO grade III cases. 
All of the non-R/R cases were WHO grade I. The R/R 
group contained 19 WHO grade I, 9 WHO grade II 
and tree WHO grade III cases according to the 1st 
neuropathological diagnosis of the first surgical 
specimen. There were 8 patients whose subsequent 
surgical specimens had higher WHO grade than the 
first; 15 patients whose first and last cases both 
showed the same grade; and 6 patients who only 
had 1 histological sample and the recurrence/relapse 
was diagnosed by imaging techniques.
The histological subtypes were not statistically 
different between the R/R group and non-R/R group: 
there were 6 meningothelial, 5 transitional, 3 fibrous 
and 2 psammomatous in the non-R/R group, while 
9 meningothelial, 6 transitional, 3 fibrous, one psam-
momatous, one clear cell, 8 atypical and 3 anaplastic 
in the R/R group. There was no increased tendency 
for recurrence for any WHO grade 1 subtype. Among 
grade 2-3 meningiomas, there was no specific sub-
type which had higher frequency of recurrence than 
the respective grade in general.
There is a significant correlation between WHO 
tumour grade and Mib1 LI (%) (p < 0.001), Mib1 stain-
ing intensity (p = 0.001), Mib1 histoscore (p < 0.001), 
p53 staining intensity (p < 0.001), p53 histoscore 
(p = 0.031), PR LI (%) (p < 0.001), PR intensity 
(p < 0.001) and PR histoscore (p < 0.001), respective-
ly (Kruskal-Wallis test). Comparing only grade I and 
grade II tumours there is a  significant correlation 
with Mib1 LI (%) (p < 0.001), Mib1 intensity (p < 0.001), 
Mib1 histoscore (p < 0.001), p53 intensity (p = 0.001), 
PR LI (%) (p = 0.014), PR intensity (p = 0.029) and 
PR histoscore (p = 0.013). Comparing grade II and 
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Table I. Comparison of grade I, grade II and grade III cases with Kruskal-Wallis test, and the WHO grade 
pairs with Mann-Whitney test. Immunostain percentage, intensity (average intensity of cells: 0, 1, 2 or 3) 
and histoscore (intensity × percentage) for Mib1, p53 and pogesterone receptor (PR)
 Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Kruskal-
Wallis
0.000 0.001 0.000 0.316 0.000 0.031 0.000 0.000 0.000
Mann-
Whitney
grade I-II
0.000 0.000 0.000 0.272 0.001 0.065 0.014 0.029 0.013
Mann-
Whitney
grade II-III
0.449 0.320 0.831 0.654 0.049 0.376 0.008 0.008 0.009
Mann-
Whitney
grade I-III
0.000 0.086 0.000 0.198 0.000 0.023 0.000 0.000 0.000
grade III tumours there is a  significant correlation 
with p53 intensity (p = 0.049), PR LI (%) (p = 0.008), 
PR intensity (p = 0.008) and PR histoscore (p = 0.009). 
When comparing grade I and grade III tumours there 
is a significant correlation of the higher grade with 
increased Mib1 LI (%) (p < 0.001), Mib1 histoscore 
(p < 0.001), p53 intensity (p < 0.001), p53 histoscore 
(p = 0.023), PR LI (%) (p < 0.001), PR intensity (p < 0.001), 
PR histoscore (p < 0.001) (Mann-Whitney test) (Ta - 
ble I, Fig. 4).
Irrespective of the grades of the R/R group, com-
paring the non-R/R and R/R groups there is a signif-
icant correlation with the Mib1 LI (%) (p < 0.001), 
Mib1 intensity (p = 0.004), Mib1 histoscore (p < 
0.001), p53 LI (%) (p = 0.027), and the WHO grade 
(p = 0.003) (Fig. 5). In WHO grade I tumours in the 
R/R group there is a significant correlation with the 
Mib1 LI (%) (p = 0.009), Mib1 histoscore (p = 0.029), 
p53 LI (%) (p = 0.032), p53 histoscore (p = 0.038) 
(Table II, Fig. 6).
Table II. Comparison of the non-recurrence/relapse (non-R/R) cases and recurrence/relapse (R/R) cases’ first 
surgical specimens without regarding the grade (first row) and only in WHO grade I cases (second row)
 Grade Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Mann-
Whitney 
any 
grades
0.003 0.000 0.004 0.000 0.027 0.955 0.069 0.207 0.497 0.215
Mann-
Whitney 
grade I
1.000b 0.009b 0.126b 0.029b 0.032b 0.195b 0.038b 0.708b 0.708b 0.858b
Table III. Comparison of the first and last surgical specimens of the recurrence/relapsed (R/R) cases with 
Mann-Whitney test (first row) and Wilcoxon signed rank test (second row). Immunostain percentage, inten-
sity (average intensity of cells: 0, 1, 2 or 3) and histoscore (intensity x percentage) for Mib1, p53 and pro-
gesterone receptor (PR)
 Grade Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Mann-
Whitney 
progression
0.001 0.002 0.098 0.001 0.861 0.006 0.553 0.154 0.154 0.159
Wilcoxon 
progression
0.007 0.042 0.237 0.050 0.042 0.484 0.559 1.000 0.545 0.876
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Fig. 5. Percentage (%), intensity (0, 1+, 2+, 3+) and histoscore (intensity x percentage) of immunostain with 
Ki-67 (clone Mib1) (A), and p53 (B) for non-reccurence/relapse (non-R/R) and reccurence/relapse (R/R) cases, 
without regarding the WHO grades.
In the R/R groups when comparing the first case 
with the recurrent/relapsed cases there is a signif-
icant difference between the Mib1 LI (%) (p = 002), 
Mib1 histoscore (p = 0.001), p53 intensity (p = 0.006) 
and the grade (p = 0.001); and with Wilcoxon signed 
rank test when compared the first and last case of 
the same patient, there is a significant difference in 
the grade (p = 0.007), Mib1 LI (%) (p = 0.042), Mib1 
histoscore (p = 0.050), and p53 LI (%) (p = 0.042) 
(Table III, Fig. 7).
According to our data, the WHO grade has strong 
forward proportion to Mib1 and p53 and an inverse 
proportion to the PR immunostain (as shown in 
several previous papers). As a  quantitative mark-
er the Mib1 has a  better correlation with percent-
age, whereas p53 with intensity and histoscore. 
Therefore, the panel of PR, p53, Mib1 is sufficient to 
characterize meningioma immunohistochemically 
regarding the risk of recurrence as an integral part 
of the routine diagnostic histopathological practice.
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Fig. 6. Percentage (%), intensity (0, 1+, 2+, 3+) and histoscore (intensity x percentage) of immunostain 
with Ki-67 (clone Mib1) (A), and p53 (B) for non-reccurence/relapse (non-R/R) and WHO grade I of the rec-
curence/relapse (R/R) cases.
Discussion
Meningioma is one of the most common intra-
cranial tumours with high incidence in the neuro-
surgical practice. The histological subtypes are well 
characterised by the WHO, and the grading is based 
on these histological characteristics, morphological 
findings and the mitotic ratio. The Simpson Grading 
System also can provide further information of the 
probability of the recurrence [30]. 
The aim of this study was to establish an easy-
to-use immunohistochemical panel for the routine 
neuropathological use, which can predict meningi-
oma relapse/recurrence. This is particularly relevant 
for tumours in problematic localization (e.g. falx 
meningiomas).
For validation we analysed the changes in immu-
nohistochemical characteristics and expression pat-
terns during relapse/recurrence and their relation to 
tumour grade.
Meningiomas usually are non-infiltrative neo-
plasms therefore complete surgical resection is cura-
tive. However, the tumour may spread laterally in small 
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Fig. 7. Percentage (%), intensity (0, 1+, 2+, 3+) and histoscore (intensity x percentage) of immunostain with Ki-67 
(clone Mib1) (A), and p53 (B) for the 1st, 2nd and last surgical specimens of the recurrence/replased (R/R) cases.
nests in the dura mater which could be a source of 
recurrence. Hence no chemotherapy is effective even 
in high grade meningiomas – radiotherapy increases 
malignant transformation [33] – another argument 
for discovery of relatively simple predictive markers of 
tumour progression and recurrence.
Although the Mib1 labelling index can be different 
according to which laboratory-performed reaction 
[8], standardized method can help the data interpre-
tation and comparison both for routine and experi-
mental practice. In accordance with previous stud-
ies the higher initial Mib1 LI has a predictive value 
regarding increased probability of recurrence. In R/R 
cases during evolution in time (i.e. time between 1st 
and last surgical procedure) there was an increase in 
Mib1 LI consistent with the known fact that tumour 
progression may occur over time which is reflected 
by increased proliferative potential and higher WHO 
grade.
The routinely used p53 antibody does not differ-
entiate between the wild type and the mutant pro-
tein. Interestingly, the p53 LI and histoscore (but not 
the labelling intensity) has an inverse correlation with 
the chance of recurrence in the WHO grade I tumours 
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in our study, but if we examine all the WHO grades, 
the increased staining in the higher grades, chang-
es to forward proportion, similarly to prior studies 
[7,14,15]. This may be explained by the fact that the 
p53 immunoreactivity does not distinguish between 
the wild type (WT) and mutant protein; in non-re-
current cases increased normal protein may have 
a beneficial effect as p53 is involved in DNA damage 
repair. In contrast, in recurrent cases p53 is more like-
ly to be mutant and ineffective thereby contributing 
to tumour growth and recurrence. Mutation analy-
sis could answer this problem, however, the focus of 
our study is on immunohistochemical markers, and 
therefore it is beyond the scope of the current proj-
ect. Today the antibodies specific to mutated p53 are 
not routinely used therefore not applied in this study. 
The p53 LI and histoscore decreased during time to 
recurrence which may indicate decreased levels of 
WT protein.
PR has an inverse relation with tumour grade in 
concert with previous reports [10,18,20,25] with no 
predictive value regarding recurrence.
Using p53 and Ki-67 molecular markers and the 
relatively simple and quick assessment method the 
increased risk of recurrence can be reliably predict-
ed. However, it is foreseeable that the presented 
method has the potential for further improvement 
with the use of digitalized histological specimens, 
because this enables automated quantitative image 
analysis as an integral component of the diagnostic 
process.
In summary, we have demonstrated a rather sim-
ple immunohistochemistry-based method with rou-
tinely used molecular markers to identify patients 
with increased risk of recurrence. Further work is 
needed to validate our work in more patients, mul-
tiple centres and in a prospective manner with long 
follow-up. The combination of histological, surgical 
and imaging markers may be a more sensitive tool 
to predict recurrence and this can also be tested in 
future studies.
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